BioSpace News Archive

This updated, post-hoc analysis included a median follow-up of more than three years, which is the longest to date of any Phase 3 study of a CDK 4/6 inhibitor.

When fully recruited, it is planned that there will be 50 participating sites, all located in the U.S.

As part of the agreement, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes.

The new assay detects Adenovirus, human Metapneumovirus, and Rhinovirus.

This registration allows Varian to market this new system in Brazil.

These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.

Liminal and Florey aim to have between 750 and 1,000 participants by the end of the year.

3dbiosurfaces and STRATEC Consumables GmbH, a wholly owned subsidiary of STRATEC, announced today the release of the first commercially available microarray substrate based on 3dbiosurfaces patented and patent-pending technologies.

In her newly expanded role, Batta will be responsible for the successful execution of the company’s commercial strategy both organically and through strategic alliances for both the Fertilome test and the Polaris® analytics platform, as well as helping to evaluate opportunities for international expansion.

Gamma secretase is an enzyme that cleaves a set of transmembrane proteins, including BCMA. Multiple publications have shown that treatment with GSIs can increase surface expression of BCMA on tumors, particularly multiple myeloma.